Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-20
2006-06-20
Wehbe′, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S325000, C435S455000, C424S199100, C424S231100, C424S134100
Reexamination Certificate
active
07064111
ABSTRACT:
A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression.
REFERENCES:
patent: 6051428 (2000-04-01), Fong et al.
patent: 6310045 (2001-10-01), Barber et al.
patent: 6764675 (2004-07-01), Whitley et al.
Verma et.al.; Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389: 239-242.
Miller et.al.; Targeted vectors for gene therapy, 1995, FASEB J. 9; 190-199.
Marshall; Gene Therapy's Growing Pains, 1995, Science, vol. 269: 1050-1055.
Orkins et.al; Report and Recommendations of the Panel to Assess the NIH Ivestment in Research on Gene Therapy, 1995.
Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8(1): 53-69.
Restifo et.al.; Molecular Mechanisms Used by Tumors to Escape Immune Recognition: Immunogenetherapy and the Cell Biology of Major Histocompatibility Complex Class I: 1993, Journal of Immunotherapy 14: 182-190.
Sturmhoefel et.al.; Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant, 1999, Cancer Research59: 4964-4972.
Hollenbaugh et.al.; The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form gp39 with B cell co-stimulatory activity, 1992, The EMBRO Journal, vol. 11, No. 12: 4313-4321.
M. Albert, et al. “Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs”, The Rocekfeller University, New York, NY,Letters to Nature, 392: 86-89 (1998).
S. Baskar, et al. “Rejection of MHC Class II-Transfected Tumor Cells Requires Induction of Tumor-Encoded B7-1 and/or B7-2 Costimulatory Molecules”, The American Association of Immunologists, Bethesda, MD,The Journal of Immunology, 156: 3821-3827 (1996).
F. Cavallo, et al. “Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response”, VCH Publishers, Inc. Deerfield Beach, FL,European Journal of Immunology, 25: 1154-1162 (1995).
P. Chaux, et al. “Inflammatory Cells Infiltrating Human Colorectal Carcinomas Express HLA Class II but Not B7-1 and B7-2 Costimulatory Molecules of the T-Cell Activation”, United States and Canadian Academy of Pathology, Inc., USA,Laboratory Investigation, 74: 975-983 (1996).
L. Chen, et al. “Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-mediated Tumor Immunity”, The Rockefeller University Press, New York, NY,Journal of Experimental Medicine, 179: 523-532 (1994).
R. Denfeld, et al. “In SituExpression of B7 and CD28 Receptor Families in Human Malignant Melanoma: Relevance for T-Cell-Mediated Anti-Tumor Immunity”, Wiley-Liss, Inc., New York, NY,International Journal of Cancer, 62: 259-265 (1995).
F. Falkner, et al. “Escherichia coli gptGene Provides Dominant Selection for Vaccina Virus Open Reading Frame Expression Vectors”, American Society for Microbiology, Washington, DC,Journal of Virology, 62: 1849-1854 (1988).
F. Falkner, et al. “Transient Dominant Selection of Recombinant Vaccina Viruses”, American Society for Microbiology, Washington, DC,Journal of Virology, 64: 3108-3111 (1990).
J. Galea-Lauri, et al. “Novel costimulators in the immune gene therapy of cancer”, Nature Publishing Group, New York, NY,Cancer Gene Therapy, 3:202-214 (1996).
J. Heuer, et al. “Retrovirus-Mediated Gene Transfer of B7-1 and MHC Class II Converts a Poorly Immunogenic Neurblastoma into a Highly Immunogenic One”, Mary Ann Liebert, Inc., Larchmont, NY,Human Gene Therapy, 7: 2059-2068 (1996).
A. Huang, et al. “Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens”, American Association for the Advancement of Science, Washington, DC,Science, 264: 961-965 (1994).
E. Katsanis, et al. “Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity”, Nature Publishing Group, New York, NY,Cancer Gene Therapy3: 75-82 (1996).
E. Katsanis, et al. “B7-1 Expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules”, Nature Publishing Group, New York, NY,Cancer Gene Therapy, 2: 39-46 (1995).
Y. Li, et al. “Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors”, The Rockefeller Univeristy Press, New York, NY,Journal of Experimental Medicine, 183: 639-644 (1996).
S. Miyatake, et al. “Defective herpes simlex virus vectors expressing thymidine kinase for the treatment of malignant glioma”, Nature Publishing Group, New York, NY,Cancer Gene Therapy, 4: 222-228 (1997).
P. Mroz, et al. “Retrovirally TransducedEscherichia coli gptGenes Combine Selectability with Chemosensitivity Capable of Mediating Tumor Eradication”, Mary Ann Liebert, Inc., Larchmont, NY,Cancer Gene Therapy, 4: 589-595 (1993).
D. Mueller, et al. “Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Occupancy”, Annual Reviews, Inc., Palo Alto, CA,Annual Review of Immunology, 7:445-480 (1989).
I. Parney, et al. “Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse-Human Glioblastoma Multiforme Model”, Mary Ann Liebert, Inc., Larchmont, NY,Human Gene Therapy, 8: 1073-1085 (1997).
J. Rao, et al. “IL-12 Is an Effective Adjuvant to Recombinant Vaccina Virus-Based Tumor Vaccines”, The American Association of Immunologists, Bethesda, MD,The Journal of Immunology, 156: 3357-3365 (1996).
R. Schwartz, et al. “T Cell Anergy”, Scientific American, Inc., New York, NY,Scientific American, 62-71 (1993).
M. Toda, et al. “In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity”, The American Association of Immunologists, Bethesda, MD,The Journal of Immunology, 160: 4457-4464 (1996).
L. Zitvogel, et al. “Interlukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors”, VCH Verlagsgesellschaft mbH, Weinheim Germany,European Journal of Immunology, 26:1335-1341 (1996).
WJR Hirst, et al. “Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1”, Stockton Press, Basingstoke, UK,Gene Therapy, 4: 691-699 (1997).
W. Marti, et al. “Nonreplicating Recombinant Vaccina Encoding Human B-7 Molecules Elicits Effective Costimulation of Naïve and Memory CD4+T Lyumphocytesin Vitro”, Academic Press, San Diego, CA,Cellular Immunology, 179: 146-152 (1997).
K. Sturmhoefel, et al. “Potent Activity of Soluble B7-IgG Fusion Porteins in Therapy of Established Tumors and as Vaccine Adjuvant”, American Association for Cancer Research, Philadelphia, PA,Cancer Research, 59: 4964-4972 (1999).
H. Swiniarski, et al. “Immune Response Ehancement byin VivoAdministration of B7.21g, a Soluble Costimulatory Protein”, Academic Press, San Diego, CA,Clinical Immunology, 92: 235-245 (1999).
M. Moro, et al. “Induction of Therapeutic T-Cell Immunity by Tumor Targeting with Soluble Recombinant B7-Immunoglobulin Costimulatory Molecules”, American Association for Cancer Research. Philadelphia, PA,Cancer Research, 59: 2650-2656 (1999).
P. Challita-Eid, et al. ȁ
Martuza Robert L.
Rabkin Samuel D.
Todo Tomoki
Foley & Lardner LLP
Georgetown University
Wehbe′ Anne M.
LandOfFree
Use of soluble costimulatory factor for tumor immuno-gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of soluble costimulatory factor for tumor immuno-gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of soluble costimulatory factor for tumor immuno-gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3689222